

# Resource Summary Report

Generated by ASWG on Sep 1, 2026

## Human EGFR (Research Grade Cetuximab Biosimilar) Biotinylated Antibody

RRID:AB\_2942016

Type: Antibody

### Proper Citation

R and D Systems Cat# FAB9577B, RRID:AB\_2942016

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2942016](http://antibodyregistry.org/AB_2942016)

**Proper Citation:** R and D Systems Cat# FAB9577B, RRID:AB\_2942016

**Target Antigen:** EGFR

**Host Organism:** Human

**Clonality:** monoclonal

**Comments:** Applications: Flow Cytometry, Immunocytochemistry

**Antibody Name:** Human EGFR (Research Grade Cetuximab Biosimilar) Biotinylated Antibody

**Description:** This monoclonal targets EGFR

**Target Organism:** Human

**Clone ID:** Hu1

**Antibody ID:** AB\_2942016

**Vendor:** R and D Systems

**Catalog Number:** FAB9577B

**Alternative Catalog Numbers:** FAB9577B-100

**Record Creation Time:** 20250820T053426+0000

**Record Last Update:** 20250820T215400+0000

---

## Ratings and Alerts

No rating or validation information has been found for Human EGFR (Research Grade Cetuximab Biosimilar) Biotinylated Antibody.

No alerts have been found for Human EGFR (Research Grade Cetuximab Biosimilar) Biotinylated Antibody.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [ASWG](#) .

Govindarajan M, et al. (2026) Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target. Cell reports. Medicine, 7(2), 102578.

Shukla D, et al. (2025) Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy. Molecular therapy : the journal of the American Society of Gene Therapy.

Reincke SM, et al. (2023) Chimeric autoantibody receptor T??cells deplete NMDA receptor-specific B cells. Cell, 186(23), 5084.